Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 9/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178795 | 0.85 | NTRK1 (0.39) | PI4KBNTRK1SCN9ASCN10A | |
| SCHEMBL16178725 | 0.81 | HDAC1 (0.42) | NTRK1 | |
| SCHEMBL16178743 | 0.81 | REN (0.38) | NTRK1RENSCN9ASCN10A | |
| SCHEMBL16178714 | 0.80 | NTRK1 (0.39) | PI4KBNTRK1SCN9ASCN10A | |
| SCHEMBL16177994 | 0.80 | PI4KB (0.50) | PI4KBNPC1RAB9A | |
| SCHEMBL16178736 | 0.79 | PI4KB (0.51) | PI4KBNTRK1NNMTSCN9ASCN10A | |
| SCHEMBL16178749 | 0.76 | MAPK1 (0.43) | PI4KBNTRK1SCN9ASCN10A | |
| SCHEMBL16178789 | 0.76 | NTRK1 (0.41) | PI4KBNTRK1SCN9ASCN10A | |
| SCHEMBL16178755 | 0.75 | NTRK1 (0.40) | NTRK1 | |
| SCHEMBL16178784 | 0.74 | HRH4 (0.38) | NTRK1SCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | PI4KB 800/4885NTRK1 3223/4885REN 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.